Search Results

Filter
  • 1-10 of  826,861 results for ""United States Food and Drug Administration""

Your Filters

Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Editorial & Opinion

The Next Chapter of Renal Denervation After US Food and Drug Administration Approval.

  • Authors : Vongpatanasin W; Hypertension Section (W.V.), Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas.; Cardiology Division (W.V., T.A.)., Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas.

Subjects: United States Food and Drug Administration*; United States ; Humans

  • Source: Circulation [Circulation] 2024 Mar 05; Vol. 149 (10), pp. 760-763. Date of Electronic Publication: 2024 Mar 04.Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 0147763

Record details

×
Periodical

'Damning' FDA inspection report undermines Alzheimer's drug.

Subjects: Alzheimer Disease*/Alzheimer Disease*/Alzheimer Disease*/drug therapy ; Scientific Misconduct* ; Spiro Compounds*/Spiro Compounds*/Spiro Compounds*/therapeutic use

  • Source: Science (New York, N.Y.) [Science] 2024 Mar 15; Vol. 383 (6688), pp. 1165-1166. Date of Electronic Publication: 2024 Mar 14.Publisher: American Association for the Advancement of Science Country of Publication: United States NLM ID:

Record details

×
Academic Journal

The FDA's proposed rule on laboratory-developed tests: what happens next?

  • Authors : Genzen JR; Department of Pathology, University of Utah Health, Salt Lake City, UT, US.; ARUP Laboratories, Salt Lake City, UT, US.

Subjects: United States Food and Drug Administration*; Humans ; United States

  • Source: Laboratory medicine [Lab Med] 2024 Mar 07; Vol. 55 (2), pp. 109-110.Publisher: Oxford University Press Country of Publication: England NLM ID: 0250641 Publication Model: Print Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Addressing the Challenge of Common Chronic Diseases - A View from the FDA.

Subjects: Chronic Disease*/Chronic Disease*/Chronic Disease*/therapy ; United States Food and Drug Administration*; Humans

  • Source: The New England journal of medicine [N Engl J Med] 2024 Feb 08; Vol. 390 (6), pp. 490-492. Date of Electronic Publication: 2024 Feb 03.Publisher: Massachusetts Medical Society Country of Publication: United States NLM ID: 0255562

Record details

×
Academic Journal

A Physician Attack on the FDA - Will the Supreme Court Reduce Access to Mifepristone?

  • Authors : Watson K; From the Feinberg School of Medicine, Northwestern University, Chicago.

Subjects: Abortion, Induced*/Abortion, Induced*/Abortion, Induced*/legislation & jurisprudence ; Abortion, Induced*/Abortion, Induced*/Abortion, Induced*/methods ; Mifepristone*/Mifepristone*/Mifepristone*/supply & distribution

  • Source: The New England journal of medicine [N Engl J Med] 2024 Feb 08; Vol. 390 (6), pp. 563-567. Date of Electronic Publication: 2024 Jan 24.Publisher: Massachusetts Medical Society Country of Publication: United States NLM ID: 0255562

Record details

×
Academic Journal

Point: The Need for Additional FDA Regulations in Laboratory Medicine.

  • Authors : Konnick EQ; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, United States.

Subjects: United States Food and Drug Administration* ; Clinical Laboratory Techniques*/Clinical Laboratory Techniques*/Clinical Laboratory Techniques*/standards ; Government Regulation*

  • Source: The journal of applied laboratory medicine [J Appl Lab Med] 2024 Jan 03; Vol. 9 (1), pp. 151-154.Publisher: Oxford University Press Country of Publication: England NLM ID: 101693884 Publication Model: Print Cited Medium: Print ISSN: 2576-9456

Record details

×
Academic Journal

Counterpoint: Why the FDA Should Not Regulate Laboratory-Developed Tests.

  • Authors : Leung ML; The Steve and Cindy Rasmussen Institute for Genomic Medicine, Nationwide Children's Hospital, Columbus, OH, United States.; Departments of Pathology and Pediatrics, The Ohio State University College of Medicine, Columbus, OH, United States.

Subjects: United States Food and Drug Administration*; Humans ; United States

  • Source: The journal of applied laboratory medicine [J Appl Lab Med] 2024 Jan 03; Vol. 9 (1), pp. 155-158.Publisher: Oxford University Press Country of Publication: England NLM ID: 101693884 Publication Model: Print Cited Medium: Print ISSN: 2576-9456

Record details

×
Academic Journal

Navigating the FDA regulatory landscape.

  • Authors : Scott PD; Food and Drug Administration, Center for Devices and Radiological Health, Office of Product Evaluation and Quality, Office of Neurological and Physical Medicine Devices, 10903 New Hampshire Ave., Silver Spring, MD, 20993, USA. .; Bajaj A

Subjects: Mental Disorders*/Mental Disorders*/Mental Disorders*/therapy ; United States Food and Drug Administration* ; Government Regulation*

  • Source: Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology [Neuropsychopharmacology] 2024 Jan; Vol. 49 (1), pp. 18-22. Date of Electronic Publisher: Nature Publishing Group Country of Publication: England NLM ID: 8904907 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Sociodemographic Characteristics of Adverse Event Reporting in the USA: An Ecologic Study.

  • Authors : Muñoz MA; Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA. .; Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, FL, USA. .

Subjects: United States Food and Drug Administration*; Female ; Humans

  • Source: Drug safety [Drug Saf] 2024 Apr; Vol. 47 (4), pp. 377-387. Date of Electronic Publication: 2024 Feb 14.Publisher: Adis, Springer International Country of Publication: New Zealand NLM ID: 9002928 Publication Model: Print-Electronic Cited Medium: Internet

Record details

×
Academic Journal

State-Regulated Psychedelics on a Collision Course With FDA.

  • Authors : Marks M; Project on Psychedelics Law and Regulation (POPLAR), Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School, Cambridge, Massachusetts.; Florida State University College of Law, Tallahassee.

Subjects: Hallucinogens*/Hallucinogens*/Hallucinogens*/pharmacology ; Hallucinogens*/Hallucinogens*/Hallucinogens*/therapeutic use ; State Government*

  • Source: JAMA [JAMA] 2023 Dec 26; Vol. 330 (24), pp. 2337-2338.Publisher: American Medical Association Country of Publication: United States NLM ID: 7501160

Record details

×
  • 1-10 of  826,861 results for ""United States Food and Drug Administration""